Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers
Open Access
- 16 April 2015
- journal article
- research article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 40 (11) , 2489-2498
Abstract
Given that cannabis use is increasing in the United States, pharmacological treatment options to treat cannabis use disorder are needed. Opioid antagonists modulate cannabinoid effects and may offer a potential approach to reducing cannabis use. In this double-blind, placebo-controlled human laboratory study, we assessed the effects of naltrexone maintenance on the reinforcing, subjective, psychomotor, and cardiovascular effects of active and inactive cannabis. Nontreatment-seeking, daily cannabis smokers were randomized to receive naltrexone (50 mg: n=18 M and 5 F) or placebo (0 mg; n=26 M and 2 F) capsules for 16 days. Before, during, and after medication maintenance, participants completed 10 laboratory sessions over 4–6 weeks, assessing cannabis’ behavioral and cardiovascular effects. Medication compliance was verified by observed capsule administration, plasma naltrexone, and urinary riboflavin. Relative to placebo, maintenance on naltrexone significantly reduced both active cannabis self-administration and its positive subjective effects (‘good effect’). Participants in the placebo group had 7.6 times (95% CI: 1.1–51.8) the odds of self-administering active cannabis compared with the naltrexone group. This attenuation of reinforcing and positive subjective effects also influenced cannabis use in the natural ecology. Naltrexone had intrinsic effects: decreasing ratings of friendliness, food intake, and systolic blood pressure, and increasing spontaneous reports of stomach upset and headache, yet dropout rates were comparable between groups. In summary, we show for the first time that maintenance on naltrexone decreased cannabis self-administration and ratings of ‘good effect’ in nontreatment-seeking daily cannabis smokers. Clinical studies in patients motivated to reduce their cannabis use are warranted to evaluate naltrexone’s efficacy as a treatment for cannabis use disorder.Keywords
This publication has 55 references indexed in Scilit:
- Medical marijuana laws in 50 states: Investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependenceDrug and Alcohol Dependence, 2012
- Dronabinol for the treatment of cannabis dependence: A randomized, double-blind, placebo-controlled trialDrug and Alcohol Dependence, 2011
- Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory studyPsychopharmacology, 2010
- Opioid antagonism enhances marijuana's effects in heavy marijuana smokersPsychopharmacology, 2010
- Naltrexone for the Management of Alcohol DependenceNew England Journal of Medicine, 2008
- The role of human drug self-administration procedures in the development of medicationsDrug and Alcohol Dependence, 2008
- Controversies in translational research: drug self-administrationPsychopharmacology, 2008
- Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis usersPsychopharmacology, 2007
- Abstinence rates following behavioral treatments for marijuana dependenceAddictive Behaviors, 2007
- μ opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesisBritish Journal of Pharmacology, 2006